- Home
- CSTL vs DIAX Comparison
CSTL vs DIAX Comparison
Compare CSTL & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- DIAX
- Stock Information
- Founded
- CSTL 2007
- DIAX 2005
- Country
- CSTL United States
- DIAX United States
- Employees
- CSTL N/A
- DIAX N/A
- Industry
- CSTL Medical Specialities
- DIAX Finance Companies
- Sector
- CSTL Health Care
- DIAX Finance
- Exchange
- CSTL Nasdaq
- DIAX Nasdaq
- Market Cap
- CSTL 456.2M
- DIAX 516.0M
- IPO Year
- CSTL 2019
- DIAX N/A
- Fundamental
- Price
- CSTL $18.52
- DIAX $13.64
- Analyst Decision
- CSTL Strong Buy
- DIAX
- Analyst Count
- CSTL 6
- DIAX 0
- Target Price
- CSTL $37.67
- DIAX N/A
- AVG Volume (30 Days)
- CSTL 419.5K
- DIAX 96.6K
- Earning Date
- CSTL 08-04-2025
- DIAX 01-01-0001
- Dividend Yield
- CSTL N/A
- DIAX 7.93%
- EPS Growth
- CSTL N/A
- DIAX N/A
- EPS
- CSTL N/A
- DIAX N/A
- Revenue
- CSTL $347,083,000.00
- DIAX N/A
- Revenue This Year
- CSTL N/A
- DIAX N/A
- Revenue Next Year
- CSTL $1.36
- DIAX N/A
- P/E Ratio
- CSTL N/A
- DIAX N/A
- Revenue Growth
- CSTL 38.43
- DIAX N/A
- 52 Week Low
- CSTL $15.45
- DIAX $12.80
- 52 Week High
- CSTL $35.84
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- CSTL 56.09
- DIAX 34.64
- Support Level
- CSTL $17.89
- DIAX $13.64
- Resistance Level
- CSTL $19.38
- DIAX $13.92
- Average True Range (ATR)
- CSTL 0.82
- DIAX 0.12
- MACD
- CSTL 0.26
- DIAX -0.06
- Stochastic Oscillator
- CSTL 77.46
- DIAX 1.56
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.